Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have FDG-avid and pathologically proven Stage IIA-IIIB non-small cell lung cancer.~* Patients must be considered unresectable or inoperable.~* Patients must be 18 years of age or older.~* Patients must have a Karnofsky performance (A measure general well-being and activities of daily life. Scores range between 0 and 100 where 100 represents normal and 0 represents death.) of score \> or = to 70.~* Patients must have adequate organ and marrow function.~* Patient must be willing to use effective contraception if female with reproductive capability.~* Patients must be informed of the investigational nature of this study and given written informed consent in accordance with institutional and federal guidelines.~Exclusion Criteria:~* Patients with any component of small cell lung carcinoma~* Patients with evidence of a malignant pleural or pericardial effusion~* Prior radiotherapy to the thorax such that composite radiation would significantly overdose critical structures, either per estimation of the treating radiation oncologist or defined by failure to meet normal tissue tolerance constraints~* Patients cannot tolerate concurrent chemotherapy~* Pregnant women are excluded from this study because radiation has the potential for teratogenic or abortifacient effects.~* Prisoners are excluded for this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Response-driven Adaptive RT (Type: EXPERIMENTAL): Patients will receive treatment 5 days per week, in once daily fractions, for 30 treatments with dose per fraction individually adapted over the final 9 treatments. Patients may also receive concurrent chemotherapy with Carboplatin and Paclitaxel. Patients may receive consolidation chemotherapy (carboplatin and paclitaxel) or immunotherapy (durvalumab) at the discretion of the medical oncologist.

Based on this trial design, predict the completion outcome and termination type (if applicable).